The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.
 
Mitchell Elliott
No Relationships to Disclose
 
Jesus Fuentes Antras
No Relationships to Disclose
 
Sasha Main
No Relationships to Disclose
 
Aaron Dou
No Relationships to Disclose
 
Nancy Gregorio
No Relationships to Disclose
 
Elizabeth Shah
No Relationships to Disclose
 
Emily Van de Laar
Stock and Other Ownership Interests - Bausch Health; Inivata/NeoGenomics
Travel, Accommodations, Expenses - AstraZeneca
 
Geethika Yalamanchili
Employment - Guardant Health
 
Leylah Drusbosky
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Caroline M. Weipert
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Eitan Amir
Honoraria - Gilead Sciences; Seagen
Consulting or Advisory Role - AstraZeneca; Novartis
 
Michelle B. Nadler
Honoraria - Exact Sciences; Novartis Bioventures
 
Celeste Yu
No Relationships to Disclose
 
Hal K. Berman
No Relationships to Disclose
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Philippe L. Bedard
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen Oncology; Lilly; Repare Therapeutics; Roche/Genentech; Seagen; Zymeworks
 
David W. Cescon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai; Gilead Sciences; GlaxoSmithKline; INFLEX; Lilly; Merck; Novartis; Pfizer; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); Pfizer (Inst); ProteinQure (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
Expert Testimony - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Inivata